- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05709106
A Prospective Real World Study of Rimegepant in the Treatment of Migraine
March 29, 2023 updated by: Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine
The goal of this observational study is to test the effectiveness and safety of Rimegepant in the treatment of migraine patients in real world.
The main questions it aims to answer are:
- [question 1] the effectiveness and safety of Rimegepant in the acute treatment of migraine
[question 2] the effectiveness and safety of Rimegepant in the long-term treatment of migraine.
- Participants will be asked to take Rimegepant when they need to treat or prevent a migraine attack.
- Participants will be asked to record the efficacy data at 0.5, 1, 2, 24, 48h post dose and report any AE to evaluate the effectiveness and safety of Rimegepant in the acute treatment of migraine
- Participants will be asked to track monthly migraine days and the use of Rimegepant, finish 2 PROs during the follow-ups, report any AE to evaluate the effectiveness and safety of Rimegepant in the long-term treatment of migraine.
Study Overview
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hainan
-
Boao, Hainan, China, 571434
- Recruiting
- Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine
-
Contact:
- Jun Liu
- Email: jly0520@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
This study will be conducted in the headache clinic of Ruijin-hainan hospital.
Participants meeting the inclusion and exclusion criteria will be enrolled continuously.
Description
Inclusion Criteria:
- Subjects diagnosed as migraines (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, beta version
- Rimegepant is prescribed by the physician for the treatment of patients with migraine.
- Patients signed written informed consent.
- Male and Female subjects ≥ 18 years and older
- Patients is not participated in other concurrent interventional clinical studies.
Exclusion Criteria:
- The patients with severe visual, hearing, language, intelligence, memory, and consciousness disorders, are unable to cooperate with the completion of the questionnaire and follow-up.
- Pregnant patients
- Lactating female patients
- Patients who are highly dependent on medical care.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Rimegepant treatment group
this group would use Rimegepant 75mg ODT, use it when needed for 1year
|
Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline on the percentage of participants that are pain relief at 2 hours post-dose during the migraine attack
Time Frame: Difference between baseline and 2 hours post-dose of Rimegepant
|
Pain Relief at 2 hours post-dose will be assessed using the number of subjects that report a pain level of moderate or severe at baseline and then report a pain level of none or mild at two hours post-dose.
|
Difference between baseline and 2 hours post-dose of Rimegepant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline on percentage of participants that are pain relief at 0.5,1,24 and 48 hours post-dose during the migraine attack
Time Frame: Difference between baseline and 0.5, 1, 24 and 48 hours post-dose of Rimegepant
|
Pain Relief at 0.5,1,24 and 48 hours post-dose will be assessed using the number of subjects that report a pain level of moderate or severe at baseline and then report a pain level of none or mild at 0.5,1,24 and 48 hours post-dose.
|
Difference between baseline and 0.5, 1, 24 and 48 hours post-dose of Rimegepant
|
Change From Baseline on the percentage of subjects able to function normally, at 0.5, 1, 2, 24 and 48 hours post-dose, will be accessed by the Functional Disability scale
Time Frame: Difference between baseline and 0.5, 1, 2, 24 and 48 hours post-dose of Rimegepant
|
The ability to function normally will be measured using the number of subjects that self-report as "normal" on the Functional Disability scale
|
Difference between baseline and 0.5, 1, 2, 24 and 48 hours post-dose of Rimegepant
|
Change From Baseline on the percentage of participants that are pain freedom at 0.5,1, 2, 24 and 48 hours post-dose during the migraine attack
Time Frame: Difference between baseline and 0.5, 1, 2, 24 and 48 hours post-dose of Rimegepant
|
Pain freedom will be assessed using the number of evaluable subjects that report no pain at 0.5,1,2,24 and 48 hours post-dose.
Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).
|
Difference between baseline and 0.5, 1, 2, 24 and 48 hours post-dose of Rimegepant
|
Change From Baseline on the percentage of participants that are freedom from Most Bothersome Symptoms MBS (nausea, phonophobia or photophobia) at 0.5,1,2,24 and 48 hours post-dose during the migraine attack
Time Frame: Difference between baseline and 0.5, 1, 2, 24 and 48 hours post-dose of Rimegepant
|
Freedom from Most Bothersome Symptom will be measured using the number of subjects that report the absence of their MBS (nausea, phonophobia or photophobia) and will measured as (0=absent, 1=present)
|
Difference between baseline and 0.5, 1, 2, 24 and 48 hours post-dose of Rimegepant
|
Change From Baseline in the Mean Number of Migraine Days Per Month Over the 12 months follow-up period.
Time Frame: From baseline to 12 months follow-up period
|
A migraine day: any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache).
If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms.
(A month is defined as 4 weeks for the purpose of this protocol).The change from baseline was calculated as the number of monthly migraine days during the every 4 weeks of the 12 months follow-up period minus number of monthly migraine days of baseline.Baseline is defined as the number of migraine days during the last 28 days prior to the recruiting date.
|
From baseline to 12 months follow-up period
|
Change from baseline in the Migraine-Specific Quality-of-Life Questionnaire v 2.1 (MSQ) total score and Headache Impact Test (HIT-6) total score at month 3,6,12 in the 12 months follow-up
Time Frame: From baseline and month 3,6,12 in the 12 months follow-up
|
The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks.The HIT-6 is a 6-question assessment used to measure the impact headaches have on a participant's ability to function on the job, at school, at home, and in social situations.
|
From baseline and month 3,6,12 in the 12 months follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 8, 2023
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
November 30, 2024
Study Registration Dates
First Submitted
January 13, 2023
First Submitted That Met QC Criteria
January 29, 2023
First Posted (Actual)
February 1, 2023
Study Record Updates
Last Update Posted (Actual)
March 30, 2023
Last Update Submitted That Met QC Criteria
March 29, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ky2022005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Rimegepant 75 MG
-
PfizerCompleted
-
Mayo ClinicPfizerNot yet recruiting
-
PfizerBiohaven Pharmaceutical Holding Company Ltd.Active, not recruitingChronic Rhinosinusitis (CRS) With and Without Nasal PolypsUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
University of Roma La SapienzaNot yet recruiting
-
Massachusetts General HospitalCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Intergroupe Francophone de Cancerologie ThoraciqueRecruitingNon Small Cell Lung Cancer | BRAF V600EFrance
-
EMD SeronoTerminatedLupus Erythematosus, SystemicUnited States, Korea, Republic of, Bulgaria, Argentina, Mexico, Italy, Spain, Philippines, Germany, Czechia, Chile, Poland, Peru, United Kingdom, South Africa, Brazil, Russian Federation
-
EMD SeronoMerck KGaA, Darmstadt, GermanyTerminatedRelapsing Multiple SclerosisSweden, United States, Czech Republic, Russian Federation, Spain, United Kingdom, Lithuania, Ukraine, Netherlands, Canada, Germany, France, Switzerland, Australia, Belgium, Lebanon, New Caledonia
-
GlaxoSmithKlineCompletedGastroparesisAustralia